These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 25890222)

  • 1. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
    Matsuoka T; Yashiro M
    World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
    Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of brain metastases: current knowledge and new frontiers.
    Neagu MR; Gill CM; Batchelor TT; Brastianos PK
    Chin Clin Oncol; 2015 Jun; 4(2):22. PubMed ID: 26112808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
    Iovanna J; Dusetti N
    Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Molecular Pathology and Treatment of Periampullary Cancers.
    Chandrasegaram MD; Chen JW; Price TJ; Zalcberg J; Sjoquist K; Merrett ND
    Pancreas; 2016 Jan; 45(1):32-9. PubMed ID: 26348463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
    Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
    Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalising pancreas cancer treatment: When tissue is the issue.
    Sjoquist KM; Chin VT; Chantrill LA; O'Connor C; Hemmings C; Chang DK; Chou A; Pajic M; Johns AL; Nagrial AM; Biankin AV; Yip D
    World J Gastroenterol; 2014 Jun; 20(24):7849-63. PubMed ID: 24976722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics of pancreatic ductal adenocarcinoma.
    Pilarsky C; Grutzmann R
    Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targeted therapies in pancreatic cancer.
    Seicean A; Petrusel L; Seicean R
    World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
    Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 20. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.